Maryam Lustberg, Director Breast Center/Chief Breast Oncology at Yale University School of Medicine, shared a post by Lisa Larkin, Founder and Co-Director at OncoMenopause Consortium, on LinkedIn, adding:
“There are more questions than answers on the optimal menopause management after breast cancer diagnosis. And many a time no concensus.
These include:
1. Are all patients all stages and all breast cancer subtypes candidates for vaginal estrogen ?
2. Are there subsets of patients with breast cancer history who can be candidates for systemic menopausal hormone therapy?
3. What are additional evidenced based non hormonal based strategies for the management of hormone related symptoms?
4. How to best address late effects of menopause and our cancer treatments?
5. How do we encourage optimization of metabolic health and fitness in breast cancer survivors with additional complexities of menopause and cancer treatment burden ?
Multiple data gaps exist but our patients deserve nuanced discussions and a chance to make decisions taking into account their breast cancer risk factors, personal health factors and their own magnitude of symptom burden.
This session by no means will answer all the questions that need answers in this complex area but I hope will be part of a growing movement to encourage open discussions and shared decision making.
Thank you SABCS 2025 for making this an education session.”
Quoting Lisa Larkin‘s post:
“I’m looking forward to speaking with my colleagues Dr. Lustberg and Dr. Kling at the 2025 San Antonio Breast Cancer Symposium about menopause management in breast cancer survivors!
We will be discussing if and when menopausal hormone therapy (MHT) can ever be considered an option, exploring the latest evidence, guidelines, and clinical considerations for survivors.
I hope you can join us for this important session!”
More posts featuring Maryam Lustberg on OncoDaily.